Discovery and lead optimisation of a potent, selective and orally bioavailable RARß agonist for the potential treatment of nerve injury. (2019)
Attributed to:
A phase 1 trial of a retinoic acid receptor beta agonist for the treatment of spinal cord injury
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.bmcl.2019.02.011
PubMed Identifier: 30792038
Publication URI: http://europepmc.org/abstract/MED/30792038
Type: Journal Article/Review
Volume: 29
Parent Publication: Bioorganic & medicinal chemistry letters
Issue: 8
ISSN: 0960-894X